Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 261

Results For "CRO"

4634 News Found

Anuh Pharma posts Q4 FY23 PAT at Rs. 9.62 Cr
News | May 22, 2023

Anuh Pharma posts Q4 FY23 PAT at Rs. 9.62 Cr

Anuh Pharma has reported total income of Rs. 158.34 crores during the period ended March 31, 2023


Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr
News | May 22, 2023

Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr

Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023


GlaxoSmithKline Pharmaceuticals posts consolidated Q4 FY2023 PAT at Rs. 133.43 Cr
News | May 22, 2023

GlaxoSmithKline Pharmaceuticals posts consolidated Q4 FY2023 PAT at Rs. 133.43 Cr

The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023


Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr
News | May 22, 2023

Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr

Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023


Abbott India posts Q4FY23 PAT at Rs. 231.42 Cr
News | May 20, 2023

Abbott India posts Q4FY23 PAT at Rs. 231.42 Cr

The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023


Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr
News | May 20, 2023

Alkem Laboratories posts Q4 FY23 consolidated PAT slides to Rs. 70.98 Cr

The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023


Strides Puducherry facility receives EIR  from USFDA
Drug Approval | May 20, 2023

Strides Puducherry facility receives EIR from USFDA

The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.


Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting
Clinical Trials | May 20, 2023

Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement


KIMS posts Q4FY23 consolidated PAT at Rs. 93.27 Cr
News | May 19, 2023

KIMS posts Q4FY23 consolidated PAT at Rs. 93.27 Cr

The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023


Gland Pharma posts Q4 FY23 consolidated PAT at Rs. 78.68 Cr
News | May 19, 2023

Gland Pharma posts Q4 FY23 consolidated PAT at Rs. 78.68 Cr

Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023